Early relapse is associated with high serum soluble interleukin-2 receptor after the sixth cycle of R-CHOP chemotherapy in patients with advanced diffuse large B-Cell lymphoma

Anticancer Research

Volumn 32, Issue 11, 2012, Pages 5051-5057

  Yamauchi, Takahiro ^a   Matsuda, Yasufumi ^a   Takai, Mihoko ^a   Tasaki, Toshiki ^a   Tai, Katsunori ^a   Hosono, Naoko ^a   Negoro, Eiju ^a   Ikegaya, Satoshi ^a   Takagi, Kazutaka ^a   Kishi, Shinji ^a   Yoshida, Akira ^a   Urasaki, Yoshimasa ^a   Iwasaki, Hiromichi ^a   Ueda, Takanori ^a  

^a UNIVERSITY OF FUKUI   (Japan)

Author keywords

Diffuse large B cell lymphoma; R CHOP; Relapse; sIL2R

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; PREDNISOLONE; RITUXIMAB; SOLUBLE INTERLEUKIN 2 RECEPTOR; VINCRISTINE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BLOOD SAMPLING; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER REGRESSION; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; FEMALE; FOLLOW UP; HUMAN; LARGE CELL LYMPHOMA; MALE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RECURRENCE FREE SURVIVAL; SURVIVAL RATE;

AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DOXORUBICIN; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PREDNISONE; PROGNOSIS; RECEPTORS, INTERLEUKIN-2; RETROSPECTIVE STUDIES; TUMOR MARKERS, BIOLOGICAL; VINCRISTINE;

EID: 84872647510     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Morton LM, Wang SS, Devesa SS, Hartge P, Weisenburger DD and Linet MS: Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. Blood 107: 265-2676, 2006.
2. Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, Morel P, Van Den Neste E, Salles G, Gaulard P, Reyes F, Lederlin P and Gisselbrecht C: CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 346: 235-242, 2002.
3. Pfreundschuh M, Trümper L, Osterborg A, Pettengell R, Trneny M, Imrie K, Ma D, Gill D, Walewski J, Zinzani PL, Stahel R, Kvaloy S, Shpilberg O, Jaeger U, Hansen M, Lehtinen T, López-Guillermo A, Corrado C, Scheliga A, Milpied N, Mendila M, Rashford M, Kuhnt E and Loeffler M; MabThera International Trial Group. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 7: 379-391, 2006.
4. Ziepert M, Hasenclever D, Kuhnt E, Glass B, Schmitz N, Pfreundschuh M and Loeffler M: Standard International Prognostic Index remains a valid predictor of outcome for patients with aggressive CD20+ B-cell lymphoma in the rituximab era. J Clin Oncol 28: 2373-2380, 2010.
5. Gisselbrecht C, Glass B, Mounier N, Singh Gill D, Linch DC, Trneny M, Bosly A, Ketterer N, Shpilberg O, Hagberg H, Ma D, Brière J, Moskowitz CH and Schmitz N: Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol 28: 4184-4190, 2010.
6. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 329: 987-994, 1993.
7. Sehn LH, Berry B, Chhanabhai M, Fitzgerald C, Gill K, Hoskins P, Klasa R, Savage KJ, Shenkier T, Sutherland J, Gascoyne RD and Connors JM: The revised International Prognostic Index (R-IPI) is a better predictor of outcome than standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood 109: 1857-1861, 2007.
8. Ichikawa A: Prognostic and predictive significance of p53 mutation in aggressive B-cell lymphoma. Int J Hematol 71: 211-220, 2000.
9. Niitsu N, Iijima K and Chizuka A: A high serum-soluble interleukin-2 receptor level is associated with a poor outcome of aggressive non-Hodgkin's lymphoma. Eur J Haematol 66: 24-30, 2001.
10. Niitsu N, Nakamine H, Okamoto M, Akamatsu H, Higashihara M, Honma Y, Okabe-Kado J and Hirano M: Clinical significance of intracytoplasmic NM23-H1 expression in diffuse large B-cell lymphoma. Clin Cancer Res 10: 2482-2490, 2004.
11. Oki Y, Kato H, Matsuo K, Kuwatsuka Y, Taji H, Yamamoto K, Kagami Y and Morishima Y: Prognostic value of serum soluble interleukin-2 receptor level in patients with diffuse large B cell lymphoma, treated with CHOP- or RCHOP-based therapy. Leuk Lymphoma 49: 1345-1351, 2008.
12. Morito T, Fujihara M, Asaoku H, Tari A, Sato Y, Ichimura K, Tanaka T, Takata K, Tamura M and Yoshino T: Serum soluble interleukin-2 receptor level and immunophenotype are prognostic factors for patients with diffuse large B-cell lymphomas. Cancer Sci 100: 1255-1260, 2009.
13. Ennishi D, Yokoyama M, Terui Y, Asai H, Sakajiri S, Mishima Y, Takahashi S, Komatsu H, Ikeda K, Takeuchi K, Tanimoto M and Hatake K: Soluble interleukin-2 receptor retains prognostic value in patients with diffuse large B-cell lymphoma receiving rituximab plus CHOP (RCHOP) therapy. Ann Oncol 20: 526-533, 2009.
14. Jo SA, Hwang SH, Chang CL, Kim SY, Shin HJ, Chung JS, Sol MY and Lee EY: Clinical relevance of elevated levels of serum soluble interleukin-2 receptor alpha (sIL-2Ra) in patients with non-Hodgkin's lymphoma. Korean J Lab Med 30: 600-605, 2010.
15. Goto N, Tsurumi H, Goto H, Shimomura YI, Kasahara S, Hara T, Yasuda I, Shimizu M, Murakami N, Yoshikawa T, Fukuno K, Takahashi T, Kito Y, Takami T and Moriwaki H: Serum soluble interleukin-2 receptor (sIL-2R) level is associated with the outcome of patients with diffuse large B-cell lymphoma treated with R-CHOP regimens. Ann Hematol 91: 705-714, 2012.
16. Rubin LA and Nelson DL: The soluble interleukin-2 receptor: Biology, function, and clinical application. Ann Intern Med 113: 619-627, 1990.
17. Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, Lister TA, Vose J, Grillo-López A, Hagenbeek A, Cabanillas F, Klippensten D, Hiddemann W, Castellino R, Harris NL, Armitage JO, Carter W, Hoppe R and Canellos GP: Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 17: 1244-1253, 1999.
18. Nakase K, Kita K, Miwa H, Nishii K, Shikami M, Tanaka I, Tsutani H, Ueda T, Nasu K, Kyo T, Dohy H, Shiku H and Katayama N: Clinical and prognostic significance of cytokine receptor expression in adult acute lymphoblastic leukemia: interleukin-2 receptor alpha-chain predicts a poor prognosis. Leukemia 21: 326-332, 2007.
19. Kitagawa J, Hara T, Tsurumi H, Goto N, Kanemura N, Yoshikawa T, Kasahara S, Yamada T, Sawada M, Takahashi T, Shimizu M, Takami T and Moriwaki H: Serum-soluble interleukin-2 receptor (sIL-2R) is an extremely strong prognostic factor for patients with peripheral T-cell lymphoma, unspecified (PTCL-U). J Cancer Res Clin Oncol 135: 53-59, 2009.
20. Greb A, Bohlius J, Schiefer D, Schwarzer G, Schulz H and Engert A: High-dose chemotherapy with autologous stem cell transplantation in the first line treatment of aggressive non-Hodgkin lymphoma (NHL) in adults. Cochrane Database Syst Rev. 2008.